Clinical Trials Logo

Neoplastic Meningitis clinical trials

View clinical trials related to Neoplastic Meningitis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00964743 Terminated - Clinical trials for Neoplastic Meningitis

Depocyt® With Sorafenib in Neoplastic Meningitis

Start date: August 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the tolerability and side effects of oral sorafenib in combination with intrathecal DepoCyt.

NCT ID: NCT00523939 Terminated - Clinical trials for Neoplastic Meningitis

DepoCyt for Active Lymphomatous or Leukemic Meningitis

Start date: June 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the response rate of lymphomatous meningitis or leukemic meningitis to DepoCyt. The safety of DepoCyt, the number of people who respond well to the study drug, and the response of symptoms to the study drug will also be determined.

NCT ID: NCT00515788 Terminated - Clinical trials for Neoplastic Meningitis

DepoCyt Plus Temozolomide in Patients With Neoplastic Meningitis

Start date: February 2006
Phase: Phase 1
Study type: Interventional

Objectives: - To determine the safety, tolerability and maximum tolerated dose (MTD) of oral temozolomide using a 7 days on and 7 days off regimen combined with intrathecal liposomal cytarabine (DepoCyt) in patients with neoplastic meningitis from solid tumors and systemic lymphoma.

NCT ID: NCT00512460 Terminated - Lymphoma Clinical Trials

RTA 744 Injection in Patients With Leptomeningeal Disease

Start date: September 2006
Phase: Phase 1
Study type: Interventional

1. The primary objectives of this study are: 1. To determine the tolerability of RTA 744 Injection in patients with leptomeningeal disease (LMD) secondary to any type of primary tumor. 2. In a selected group of 6-10 patients who will receive RTA 744 at or near the maximum tolerated dose (MTD), to characterize the multiple-dose pharmacokinetics of RTA 744 in plasma and CSF. 2. The secondary objectives of this study are: 1. To document any potential antitumor activity of RTA 744 in this patient population. 2. To correlate pharmacokinetic information with clinical (efficacy and safety) responses, as a possible help in selecting appropriate doses for later studies.